ALS Association Statement on Positive Phase 3 Results for Ulefnersen in FUS-ALS
ARLINGTON, Va., Sept. 22, 2026 /PRNewswire/ -- The ALS Association celebrates today's news that ulefnersen, an investigational antisense therapy for people with FUS-ALS, met its primary endpoint in the Phase 3 FUSION trial. Ulefnersen is now the second antisense therapy, after Qalsody...
Short extract only — this publisher licenses its text. Read the full release at the source.
More from Commercial newswire
- Let 'Em Fly! Urban Air Adventure Park Reopens in Bloomindale with New Attractions - First 100 Guests Win Free Urban Air for a Year
- CHiQ patrocina el Abierto Juvenil de Tenis en Silla de Ruedas de Colonia
- Decoy Therapeutics, Inc. Announces a Warrant Inducement Transaction for $3.85 Million in Gross Proceeds Priced At-The-Market under Nasdaq Rules
The rest of this wire is for subscribers
Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
7 days, no card required.
Read releases like this the second they cross the wire.
1,200+ — live on PPN World right now. Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
Start the free trial →Your announcement next? Distribute your press release to the global wires with PPN Source — and track its pickup live here.
PPN Source →